From the Journal of the American Medical Association–The Food and Drug Administration (FDA) has issued a final guidance document to provide manufacturers with a framework for evaluating and labeling abuse-deterrent opioids.
This content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
Funding for this initiative was made possible (in part) by grant no. 5H79TI025595-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.